Based on feedback from our study participants on the taste, spray optimization is necessary

This double-blind, randomized, placebo-controlled study aims to investigate whether a throat spray containing probiotic bacteria (i.e. microbiome spray) can reduce the symptoms and complaints of the SARS-CoV-2 virus in patients with mild to moderate symptoms. In addition, the aim is to investigate whether the microbiome spray can prevent transmission of the SARS-CoV-2 virus to household members.

Inclusion Criteria:

• Patients in primary care with a positive SARS-CoV-2 test based on PCR
• Instructed during screening and agreed not to use other probiotic nutritional supplements outside of the study during the study period
• Sign the consent form

Exclusion Criteria:

• Antibiotic use at baseline and during the study
• Vaccinated against SARS-CoV-2 at start of the study (both for index patients and household members that participate)
• Pregnant women
• History of use of probiotic supplements in the past two weeks
• Current diagnosis of cancer or immunosuppressive therapy within the past 6 months
• Acute and chronic infectious and inflammatory upper airway diseases (eg acute / chronic rhinosinusitis)
• Clinically significant bleeding disorder
• Any other medical condition that, in the principal investigator's opinion, warrants exclusion from the trial